Cover Image
市場調查報告書

生殖器皰疹 : 開發中產品分析

Genital Herpes - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 232819
出版日期 內容資訊 英文 102 Pages
訂單完成後即時交付
價格
Back to Top
生殖器皰疹 : 開發中產品分析 Genital Herpes - Pipeline Review, H1 2017
出版日期: 2017年03月22日 內容資訊: 英文 102 Pages
簡介

生殖器皰疹是代表性的性傳染病之一,任何性別皆有可能發病。這個疾病是由單純皰疹病毒(HSV)所引起,會出現食慾衰退、發熱、倦怠感、腰部·臀部·大腿部·膝部肌肉疼痛、腳根浮腫和淋巴節疼痛等症狀。

本報告提供生殖器皰疹治療藥的開發情形相關調查,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢等資訊。

簡介

  • 調查範圍

生殖器皰疹概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

生殖器皰疹:企業開發中的治療藥

生殖器皰疹:大學/機關研究中的治療藥

生殖器皰疹:開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品

生殖器皰疹:企業開發中的產品

生殖器皰疹:大學/機關研究中的產品

生殖器皰疹的治療藥開發企業

  • Admedus Ltd
  • Agenus, Inc.
  • AiCuris GmbH & Co. KG
  • Foamix Pharmaceuticals Ltd.
  • Genocea Biosciences, Inc.
  • GenVec, Inc.
  • Immune Design Corp.
  • JN-International Medical Corporation
  • Mymetics Corporation
  • NanoBio Corporation
  • NanoViricides, Inc.
  • PaxVax, Inc.
  • Profectus BioSciences, Inc.
  • Redbiotec AG
  • Sanofi Pasteur SA
  • Shulov Innovative Science Ltd.
  • Starpharma Holdings Limited
  • Tomegavax, Inc.
  • Vaccibody AS
  • Vaxart, Inc.
  • Vical Incorporated

生殖器皰疹:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

生殖器皰疹:暫停中的計劃

生殖器皰疹:開發中止的產品

生殖器皰疹:產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9088IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Genital Herpes - Pipeline Review, H1 2017, provides an overview of the Genital Herpes (Infectious Disease) pipeline landscape.

Genital herpes is a common sexually transmitted infection that affects both men and women. Genital herpes is caused by the herpes simplex virus (HSV). Symptoms include decreased appetite, fever, general sick feeling (malaise), muscle aches in the lower back, buttocks, thighs, or knees and swollen and tender lymph nodes in the groin during an outbreak. Treatment includes antiviral medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Genital Herpes - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Genital Herpes (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Genital Herpes (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Genital Herpes and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 6, 3, 18 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Genital Herpes (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Genital Herpes (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Genital Herpes (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Genital Herpes (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Genital Herpes (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Genital Herpes (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Genital Herpes (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Genital Herpes (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Genital Herpes - Overview
  • Genital Herpes - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Genital Herpes - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Genital Herpes - Companies Involved in Therapeutics Development
    • Abivax SA
    • Admedus Ltd
    • AiCuris GmbH & Co KG
    • Biomere LLC
    • Foamix Pharmaceuticals Ltd
    • Genocea Biosciences Inc
    • GenVec Inc
    • Immune Design Corp
    • JN-International Medical Corp
    • N & N Pharmaceuticals Inc
    • NanoBio Corp
    • NanoViricides Inc
    • Profectus BioSciences Inc
    • Redbiotec AG
    • Sanofi Pasteur SA
    • Starpharma Holdings Ltd
    • Tomegavax Inc
    • Vaccibody AS
    • Vaxart Inc
    • Vical Inc
  • Genital Herpes - Drug Profiles
    • ABX-196 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • acyclovir - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Aspidasept - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • astodrimer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • G-103 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GEN-003 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • genital herpes (virus like particle) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • genital herpes vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • genital herpes vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • genital herpes vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • genital herpes vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • genital herpes vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GV-2207 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • herpes simplex virus [type 1, 2] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • herpes simplex virus 2 vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • herpes simplex virus 2 vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • herpes simplex virus 2 vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • herpes simplex virus 2 vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • herpes simplex virus 2 vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HSV-529 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NN-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pritelivir - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Profavax HSV-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Profavax HSV-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Genital Herpes - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Theravax HSV-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Theravax HSV-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VCLHB-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VCLHM-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VTMX-004 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Genital Herpes - Dormant Projects
  • Genital Herpes - Discontinued Products
  • Genital Herpes - Product Development Milestones
    • Featured News & Press Releases
      • Mar 06, 2017: NanoBio Receives SBIR Grant For Genital Herpes Vaccine
      • Jan 05, 2017: Genocea Announces Positive 6-Month Results from GEN-003 Phase 2b Clinical Trial
      • Dec 14, 2016: Genocea R&D Day Highlighted Lead Program, GEN-003, for the Treatment of Genital Herpes and Introduced Immuno-Oncology Programs & Strategy
      • Dec 01, 2016: AiCuris Announces Start of LipP 1: First Subject Enrolled in the Clinical Phase 2 Trial with Topical Pritelivir for the Treatment of recurrent Labial Herpes
      • Oct 28, 2016: Genocea Presents New 12 month Data on Genital Herpes Immunotherapy GEN-003 at IDWeek 2016
      • Oct 19, 2016: Admedus Announces Positive Unblinded HSV-2 Phase II Interim Data
      • Sep 29, 2016: Genocea's Genital Herpes Immunotherapy GEN-003 Demonstrates Significant Reduction of Viral Shedding in Phase 2b Clinical Trial
      • Jun 20, 2016: A novel therapy for genital herpes engages immune cells to provide significant patient benefits
      • Jun 20, 2016: Vicals Phase 1/2 Trial Data Presented at ASM 2016 Shows Bivalent Vaccine Imparts Reduction in Genital Herpes Lesions Durable to 9 Months
      • Jun 09, 2016: Genocea Showcases Potential of Genital Herpes Immunotherapy GEN-003 at ASM Microbe 2016
      • Mar 31, 2016: Genital Herpes Immunotherapy GEN-003 Shows Sustained Reduction of Viral Shedding Rate, Durable Impact on Clinical Disease 12 Months Post-Dosing
      • Mar 04, 2016: Interim HSV-2 Phase II clinical trial data encouraging
      • Feb 03, 2016: Model helps decide drug dose for clinical testing
      • Jan 29, 2016: Genocea Commences Dosing in Phase 2b Study for Genital Herpes Treatment, GEN-003
      • Oct 07, 2015: Genocea Announces Positive Durability Data from 6-Month Analysis of Phase 2 Clinical Trial of Genital Herpes Immunotherapy GEN-003
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Genital Herpes, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Genital Herpes - Pipeline by Abivax SA, H1 2017
  • Genital Herpes - Pipeline by Admedus Ltd, H1 2017
  • Genital Herpes - Pipeline by AiCuris GmbH & Co KG, H1 2017
  • Genital Herpes - Pipeline by Biomere LLC, H1 2017
  • Genital Herpes - Pipeline by Foamix Pharmaceuticals Ltd, H1 2017
  • Genital Herpes - Pipeline by Genocea Biosciences Inc, H1 2017
  • Genital Herpes - Pipeline by GenVec Inc, H1 2017
  • Genital Herpes - Pipeline by Immune Design Corp, H1 2017
  • Genital Herpes - Pipeline by JN-International Medical Corp, H1 2017
  • Genital Herpes - Pipeline by N & N Pharmaceuticals Inc, H1 2017
  • Genital Herpes - Pipeline by NanoBio Corp, H1 2017
  • Genital Herpes - Pipeline by NanoViricides Inc, H1 2017
  • Genital Herpes - Pipeline by Profectus BioSciences Inc, H1 2017
  • Genital Herpes - Pipeline by Redbiotec AG, H1 2017
  • Genital Herpes - Pipeline by Sanofi Pasteur SA, H1 2017
  • Genital Herpes - Pipeline by Starpharma Holdings Ltd, H1 2017
  • Genital Herpes - Pipeline by Tomegavax Inc, H1 2017
  • Genital Herpes - Pipeline by Vaccibody AS, H1 2017
  • Genital Herpes - Pipeline by Vaxart Inc, H1 2017
  • Genital Herpes - Pipeline by Vical Inc, H1 2017
  • Genital Herpes - Dormant Projects, H1 2017
  • Genital Herpes - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Genital Herpes - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Genital Herpes, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top